GlaxoSmithKline: HIV Infections trials

The registry lists 265 HIV Infections studies with GlaxoSmithKline as lead sponsor. 15 are open to participants now and 99 have results posted.

Phase 1 84Phase 2 53Phase 3 68Phase 4 18No phase 47(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Mass Balance and Absolute Bioavailability of [14C]-VH4011499Not yet recruitingNCT07934719Phase 1
• A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIVNot yet recruitingNCT07822477Phase 1
• A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult ParticipantsRecruitingNCT07818915Phase 1
• A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)Not yet recruitingNCT07816250Phase 2
• Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184RecruitingNCT07636928Phase 1
• A Study to Investigate the Safety and PK of VH4770359 in Healthy ParticipantsRecruitingNCT07525544Phase 1
• A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentRecruitingNCT07393659Phase 3
• A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1RecruitingNCT07275606Phase 1/2
• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)RecruitingNCT07202546Phase 2
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIVRecruitingNCT06724640Phase 1
• First Time in Human Study of Long Acting VH4524184 FormulationsRecruitingNCT06310551Phase 1
• Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in PediatricsRecruitingNCT05674656Phase 1/2
• A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsRecruitingNCT05418868Phase 1
• Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)AvailableNCT04233047
• Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant WomenRecruitingNCT03564613
• VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1CompletedNCT06214052Phase 2Results posted
• A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1TerminatedNCT06061081Phase 2Results posted
• Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected AdultsCompletedNCT06039579Phase 2Results posted
• A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAFCompletedNCT05911360Phase 3Results posted
• A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE TerritoriesCompletedNCT05514509Phase 4Results posted
• First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy ParticipantsCompletedNCT05393271Phase 1Results posted
• A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United StatesCompletedNCT05374525Phase 4Results posted
• A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult ParticipantsCompletedNCT05291520Phase 1Results posted
• First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy ParticipantsCompletedNCT05163522Phase 1Results posted
• Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)CompletedNCT04982445Phase 4Results posted
• A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive AdultsTerminatedNCT04900038Phase 2Results posted
• A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected AdultsCompletedNCT04871113Phase 2Results posted
• A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy ParticipantsCompletedNCT04857892Phase 1Results posted
• A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult ParticipantsCompletedNCT04827134Phase 1Results posted
• Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)CompletedNCT04630002Phase 1Results posted
• Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of MoxifloxacinCompletedNCT04563845Phase 1Results posted
• A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically SuppressedCompletedNCT04542070Phase 3Results posted
• Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254CompletedNCT04507321Phase 1Results posted
• GSK3739937 First-Time-In-Human (FTIH) Study in Healthy VolunteersCompletedNCT04493684Phase 1Results posted
• A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive AdultsTerminatedNCT04493216Phase 2Results posted
• Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult ParticipantsCompletedNCT04484337Phase 1Results posted
• Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy AdultsCompletedNCT04425902Phase 1Results posted
• A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European CountriesCompletedNCT04399551Phase 3Results posted
• Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult ParticipantsCompletedNCT04371380Phase 1Results posted
• A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy ParticipantsCompletedNCT04263142Phase 1Results posted
• A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy ParticipantsTerminatedNCT04128293Phase 1Results posted
• Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)CompletedNCT04021290Phase 3Results posted
• 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase InhibitorCompletedNCT04019873Results posted
• Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)CompletedNCT04001803Phase 3Results posted
• Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese DescentCompletedNCT03984838Phase 1Results posted
• Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral ContraceptiveCompletedNCT03984825Phase 1Results posted
• Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) StudyTerminatedNCT03984812Phase 1Results posted
• Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected AdultsCompletedNCT03945981Phase 3Results posted
• Dolutegravir Pediatric Liquid Formulation StudyCompletedNCT03921723Phase 1Results posted
• Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/EmtricitabineCompletedNCT03836729Phase 1Results posted
• Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)CompletedNCT03816696Phase 1Results posted
• A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive AdultsCompletedNCT03784079Phase 2Results posted
• Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in GermanyCompletedNCT03754803Results posted
• Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected AdolescentsCompletedNCT03682848Phase 3Results posted
• Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE StudyCompletedNCT03639311Phase 2Results posted
• A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254CompletedNCT03575962Phase 1Results posted
• Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1CompletedNCT03518060Results posted
• Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)CompletedNCT03446573Phase 3Results posted
• To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy VolunteersCompletedNCT03441984Phase 1Results posted
• A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese MenCompletedNCT03422172Phase 1Results posted
• Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)CompletedNCT03368053Phase 1Results posted
• Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsActive, not recruitingNCT03299049Phase 3Results posted
• A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without RitonavirCompletedNCT03234036Phase 1Results posted
• GSK3640254 First Time in Human (FTIH) Study in Healthy VolunteersCompletedNCT03231943Phase 1Results posted
• Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy SubjectsCompletedNCT03149848Phase 1Results posted
• Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of DolutegravirCompletedNCT03095638Phase 1Results posted
• Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected AdultsCompletedNCT03045861Phase 2Results posted
• Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019CompletedNCT03016533Phase 3Results posted
• Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsActive, not recruitingNCT02951052Phase 3Results posted
• Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsActive, not recruitingNCT02938520Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)CompletedNCT02831764Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)CompletedNCT02831673Phase 3Results posted
• Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine RegimenCompletedNCT02478632Phase 3Results posted
• Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult VolunteersCompletedNCT02478463Phase 1Results posted
• Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)CompletedNCT02429791Phase 3Results posted
• Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)CompletedNCT02422797Phase 3Results posted
• Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced AdultsTerminatedNCT02386098Phase 2Results posted
• Attachment Inhibitor Comparison in Heavily Treatment Experienced PatientsActive, not recruitingNCT02362503Phase 3Results posted
• Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line TreatmentCompletedNCT02227238Phase 3Results posted
• Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infectionCompletedNCT02178592Phase 3Results posted
• A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult SubjectsCompletedNCT02120352Phase 2Results posted
• ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus InfectionCompletedNCT02075593Phase 3Results posted
• A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)CompletedNCT01910402Phase 3Results posted
• Study to Evaluate a HIV Drug for the Treatment of HIV InfectionCompletedNCT01803074Phase 2Results posted
• Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus RilpivirineCompletedNCT01641809Phase 2Results posted
• Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or ElivitegravirCompletedNCT01568892Phase 3Results posted
• Drug Exposure Registry for GSK2248761, an Investigational NNRTICompletedNCT01458132Results posted
• A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis BCompletedNCT01327547Phase 4Results posted
• A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)CompletedNCT01263015Phase 3Results posted
• Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)TerminatedNCT01231555Phase 2Results posted
• A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive AdultsCompletedNCT01231516Phase 3Results posted
• A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice DailyCompletedNCT01227824Phase 3Results posted
• Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected PersonsCompletedNCT01218113Phase 2Results posted
• Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV InfectionTerminatedNCT01199731Phase 2Results posted
• Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1CompletedNCT01009814Phase 2Results posted
• A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive SubjectsCompletedNCT00951015Phase 2Results posted
• A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to RaltegravirCompletedNCT00950859Phase 2Results posted
• Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.CompletedNCT00945282Phase 2Results posted
• Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)CompletedNCT00920426Phase 2Results posted
• Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive ProceduresTerminatedNCT00678587Phase 3Results posted